ORLANDO, Fla. - As the opioid epidemic continues to devastate the United States, ketamine use has grown as a pain management alternative, yet more than one in three patients may experience side effects such as hallucinations and visual disturbances, suggests new research presented at the ANESTHESIOLOGY&reg; 2019 annual meeting.Ketamine is a powerful anesthetic that is also used to treat acute and chronic pain and depression. While the drug is known for some side effects that negatively affect mental status, there are many other potential risks. Recent consensus guidelines from the American Society of Regional Anesthesia and Pain Medicine, American Academy of Pain Medicine and American Society of Anesthesiologists (ASA) support ketamine infusion therapy for acute pain management, but the groups note more studies are needed to determine the best approach for using it safely and effectively.&quot;Despite the U.S. Food and Drug Administration&#39;s approval of ketamine for multiple uses, including general anesthesia and treatment of depression, the effects of using the drug at low doses to treat pain have not been extensively studied,&quot; said Padma Gulur, M.D., lead author, member of ASA&#39;s Committee on Pain Medicine and professor of anesthesiology at Duke University in Durham, North Carolina. &quot;Our research aimed to determine both short- and long-term side effects of low dose ketamine when used for pain treatment.&quot;Researchers conducted a review of side effects related to ketamine infusions for pain management. Reported side effects were categorized into two groups: those directly linked to ketamine (hallucinations, vivid dreams, out-of-body experience and/or unusual thoughts) and those associated with using ketamine in combination with other drugs (sedation, visual disturbances and urinary dysfunction).Of 297 Duke University pain patients who received ketamine infusion therapy between January and June 2017, 104 (35%) reported significant side effects. Twenty percent of these patients suffered side effects directly linked to ketamine, while 15% experienced side effects associated with the use of ketamine in combination with other drugs.&quot;Although the opioid epidemic has prompted the medical community to thoroughly investigate pain management alternatives, our number one priority is to ensure the safety of patients receiving ketamine,&quot; said Dr. Gulur. &quot;More than one in three patients reported significant side effects from ketamine infusions that required ongoing monitoring or resulted in discontinuation of therapy. More research on the impact of ketamine use for pain on the population is needed.&quot;###THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 53,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount. Join the ANESTHESIOLOGY&reg; 2019 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES19.Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

As the opioid epidemic continues to devastate the United States, ketamine use has grown as a pain management alternative, yet more than one in three patients may experience side effects such as hallucinations and visual disturbances, suggests new research presented at the ANESTHESIOLOGY® 2019 annual meeting. Ketamine is a powerful...

One in Three Pain Patients Suffer Side Effects After Ketamine Infusion Therapy

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival.
Patients are living years longer, thanks to novel combination therapies with immunomodulatory drugs, proteasome inhibitors, CAR T-cell therapies, and monoclonal and bispecific antibodies.
In addition, high-dose chemotherap

The Wealth and Complexity of Treatment Options for Relapsed/Refractory Multiple Myeloma

Although the multiple myeloma treatment landscape has evolved substantially in recent years, several “gray zones” of clinical uncertainty remain, particularly regarding optimal integration of novel therapies, according to Ajai Chari, MD.
At the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma meeting, Chari and colleagues del

Clinical "Gray Areas" Persist Amid Evolving Multiple Myeloma Treatment Strategies

(HealthDay News) — Breast cancer survivors have a lower risk of Alzheimer’s disease than cancer-free control individuals, according to a study published in JAMA Network Open.
Researchers examined the risk of Alzheimer’s disease among breast cancer survivors and cancer-free control individuals using data from the Korean National Health Insurance Ser

Breast Cancer Survivors May Have Lower Risk of Alzheimer's Disease

A real-world, multicenter study of 67 evaluable patients treated with fecal microbiota, live-jslm (RBL), demonstrated a 77.6% treatment success rate at 8 weeks for preventing recurrent Clostridioides difficile infection (rCDI), with 87% maintaining remission at six months. These findings support RBL’s safety and efficacy beyond controlled clinical

Real-World Use of Fecal Microbiota, live-jslm Shows High Success in Preventing Recurrent C difficile Infection

Clinical outcomes and disease severity among older adults hospitalized with respiratory syncytial virus infection were influenced by frailty status, with increased frailty linked to greater risk for severe disease presentation.
Frailty serves as a significant predictor of severe respiratory syncytial virus (RSV) outcomes in hospitalized older adult

Frailty Status Predicts Severity of RSV Infection in Hospitalized Older Adults

During a Between the Lines program at the European Lung Cancer Conference 2025 in Paris, France, the phase 3 MARIPOSA trial (NCT04487080) assessing amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) vs osimertinib (Tagrisso) for patients with non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or L858R mutations was the center

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

Vivasure Medical has announced the submission of a premarket approval application to the US Food and Drug Administration (FDA) for its PerQseal Elite vascular closure system for arterial procedures.
In a recent press release the company has stated that the submission builds upon the successful results of the PATCH study as well as positive clinical

Vivasure Medical submits premarket approval to US FDA for PerQseal Elite closure system

After a median follow-up period of approximately 7 years, daratumumab continued to show single-agent clinical activity among patients who have been diagnosed with smoldering multiple myeloma (SMM) of intermediate-to-high risk, with no new safety signals, according to a study published in Blood.
Smoldering multiple myeloma (SMM) is a precursor to ac

Daratumumab Shows Promise in Patients With Intermediate-to-High Risk Smoldering MM

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH t

FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial

The vaccine, called mRNA-1010, worked better than a standard-dose flu vaccine, providing 26.6% more protection against the flu overall.
HealthDay News — Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced Monday.
The vaccine, called mRNA-1010, was t

Moderna's New Flu Shot Shows Strong Results in Older Adults

A survey of more than 20,000 patients revealed a lack of trust in information about cancer, whether it comes from scientists, doctors, or other sources. Results from the survey were presented at the ASCO Annual Meeting 2025.
For this study, researchers analyzed data from the Health Information National Trends Survey (2017-2022). The cohort included

Survey Reveals Lack of Trust in Cancer Information From Experts, Other Sources

HealthDay News — Fluctuations in ovarian sex hormones across the menstrual cycle may influence women’s likelihood of alcohol consumption, according to a study presented at the annual scientific meeting of the Research Society on Alcohol, held June 21 to 25 in New Orleans.
Layne Robinson, from University of Kentucky in Lexington, and colleagues asse

Menstrual Cycle Phases May Be Linked to Higher Alcohol Craving, Drinking

Gynecological Cancers: Treatment Updates and Expert Perspectives : Episode 6
Opinion
Video
July 1, 2025
Author(s):
Thomas C. Krivak, MD
Newsletter
Stay up to date on the most recent and practice-changing oncology data
Subscribe Now!
Latest CME
View All
Audio
PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic L

Recent Advances and Future Direction in Ovarian Cancer Treatments

In 2023, the United States reported 2,770 cases of nationally notifiable arboviral diseases, with West Nile virus (WNV) accounting for 95% of those cases, according to a CDC report published in MMWR. These infections resulted in 2,022 hospitalizations (73%) and 208 deaths (8%), with the majority of illnesses occurring from July through September.1

West Nile Virus Dominated Arboviral Cases in 2023, as CDC Reports First US Infection With Lineage 3 Strain

Taurolidine IV lock reduces recurrent CRBSI
Abstract:
Background & aims: Recurrent catheter-related bloodstream infections (CRBSIs) are a frequent, severe, and costly complication of home parenteral support (HPS) in patients with chronic intestinal failure (CIF). While taurolidine-containing catheter locks have shown potential in preventing CRBSIs,

Taurolidine IV lock reduces recurrent CRBSI – Full Text

The panel discussed a patient who is currently at her third line of therapy for metastatic HER2-positive breast cancer with brain metastases. Given her disease status, the preferred next step is a regimen known to be effective in this setting, especially for patients with active central nervous system (CNS) involvement. A commonly used treatment wi

Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond

The treatment of chronic lymphocytic leukemia (CLL) is evolving and new data presented at the EHA 2025 Congress demonstrated significant improvements in outcomes for treatment-naïve patients as well as those who have relapsed/refractory (R/R) disease. The progress seen in non-chemotherapeutic options is changing the paradigm in CLL in particular fo

Treatment Regimens Improving QoL and PFS in Patients With CLL

Contact

Advertise

Other industries

Empower vascular access teams with tools that streamline workflows, enhance teamwork, and improve outcomes.

Tools for Efficient Vascular Access | Salubrity Online

Gebauer’s Pain Ease® works in just 4-10 seconds!

Give patients the comfort they deserve

Ivenix Infusion System

You have several options—but you also have several reasons to choose one above the rest.
Learn more now.


Prescribing IVIg?

AVA Consensus Statement recommend adhesives like gum mastic to secure PIVC dressings and devices.